Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
AGN [NYSE]
Allergan Inc.
IndexS&P 500 P/E43.35 EPS (ttm)4.37 Insider Own9.90% Shs Outstand297.18M Perf Week3.31%
Market Cap56.30B Forward P/E22.46 EPS next Y8.43 Insider Trans0.05% Shs Float296.61M Perf Month5.44%
Income1.32B PEG2.14 EPS next Q1.68 Inst Own93.60% Short Float1.31% Perf Quarter14.42%
Sales6.75B P/S8.34 EPS this Y17.60% Inst Trans-0.15% Short Ratio1.61 Perf Half Y11.57%
Book/sh22.80 P/B8.31 EPS next Y37.90% ROA11.90% Target Price206.94 Perf Year107.74%
Cash/sh12.50 P/C15.15 EPS next 5Y20.29% ROE19.50% 52W Range88.20 - 192.98 Perf YTD70.71%
Dividend0.20 P/FCF39.38 EPS past 5Y17.90% ROI15.70% 52W High-1.67% Beta0.72
Dividend %0.11% Quick Ratio3.80 Sales past 5Y7.40% Gross Margin87.80% 52W Low115.14% ATR5.70
Employees11700 Current Ratio4.10 Sales Q/Q16.70% Oper. Margin30.70% RSI (14)64.17 Volatility2.40% 3.26%
OptionableYes Debt/Eq0.32 EPS Q/Q17.10% Profit Margin18.70% Rel Volume0.67 Prev Close189.44
ShortableYes LT Debt/Eq0.31 EarningsOct 27 BMO Payout4.60% Avg Volume2.41M Price189.75
Recom1.70 SMA203.45% SMA508.52% SMA20023.45% Volume1,342,768 Change0.16%
09-Oct-14Initiated Deutsche Bank Buy $215
01-Oct-14Upgrade Stifel Hold → Buy $200
22-Jul-14Upgrade UBS Neutral → Buy $180 → $200
28-Apr-14Downgrade Stifel Buy → Hold
22-Apr-14Downgrade Argus Buy → Hold
07-Mar-14Reiterated Barclays Equal Weight $95 → $130
07-Feb-14Reiterated Argus Buy $110 → $130
08-Jan-14Reiterated Argus Buy $110 → $125
07-Jan-14Initiated RBC Capital Mkts Outperform $131
20-Dec-13Reiterated UBS Buy $100 → $116
20-Dec-13Reiterated BMO Capital Markets Outperform $112 → $117
31-Oct-13Reiterated Argus Buy $118 → $110
25-Jun-13Reiterated Canaccord Genuity Hold $111 → $98
24-Jun-13Downgrade Deutsche Bank Buy → Hold
02-May-13Reiterated RBC Capital Mkts Outperform $123 → $119
06-Feb-13Reiterated Stifel Nicolaus Buy $110 → $118
06-Feb-13Reiterated Canaccord Genuity Hold $102 → $111
22-Jan-13Reiterated Canaccord Genuity Hold $101 → $102
19-Sep-12Initiated Canaccord Genuity Hold $101
30-Mar-12Reiterated RBC Capital Mkts Outperform $93 → $106
31-Oct-14 10:54AM  Cramer on the Stock Market: Find the Best of Best-of-Breed Stocks at TheStreet
10:20AM  AbbVie Q3 Earnings Top on Humira Sales, Boosts Outlook Zacks
30-Oct-14 02:35PM  Sanofi Beats on Q3 Earnings but Lantus Outlook Disappoints Zacks
08:55AM  Is Valeant the wrong partner for Bill Ackmans bid for Allergan? at Fortune
28-Oct-14 09:56PM  Allergan seeks to bar Bill Ackman from voting amid takeover bid at Los Angeles Times
04:10PM  The Consequences of Saying No to a Hostile Takeover Bid at New York Times
03:48PM  Ackman-Allergan Enters Courtroom Phase: Opening Line at Bloomberg
03:10PM  Pfizer Q3 Earnings Top Estimates Despite Generic Pressure Zacks
02:44PM  Allergan (AGN) Earnings Report: Q3 2014 Conference Call Transcript at TheStreet
11:18AM  Ackman & Allergan in court CNBC
09:38AM  Stock Market News for October 28, 2014 Zacks
09:08AM  Cramer: Pfizer flatlining CNBC
06:12AM  Novartis' precision M&A plan: CEO CNBC
12:56AM  [$$] Valeant Hints at Higher Allergan Bid at The Wall Street Journal
12:01AM  Ackmans $5.3 Billion Allergan Bet Examined Before Vote at Bloomberg
27-Oct-14 08:10PM  Valeant says it's willing to raise offer for Allergan to $200 a share at Los Angeles Times
07:23PM  Jim Cramer's 'Mad Money' Recap: How Do You Make Money in a Clueless Market? at TheStreet
06:26PM  Takeover drama for your mama: Cramer reveals at CNBC
06:15PM  Allergan CEO: Huge momentum in sales growth CNBC
06:00PM  Cramer: Dazed and confused market CNBC
05:30PM  AstraZeneca's Lynparza a Step Closer to European Approval Zacks
01:45PM  Valeant willing to raise offer for Botox maker Allergan at Financial Times
12:56PM  Dealpolitik: Path to Nowhere in Allergan Litigation? at The Wall Street Journal
12:47PM  [$$] Valeant Hints at Higher Allergan Bid at The Wall Street Journal
12:17PM  Video: Allergan Lifts Views; Valeant Suggests Higher Bid at Investor's Business Daily
11:44AM  Allergan firms up its profit as it continues to rebuff Valeants advances at Fortune
11:34AM  Valeant Pharmaceuticals Eyes Raising Allergan Bid to $200 a Share at TheStreet
11:31AM  Valeant says it's willing to boost offer for Botox maker Allergan at Los Angeles Times
11:15AM  Valeant Raises Allergan Takeover Bid Benzinga
11:14AM  Valeant: We'll bump Allergan offer to $200 a share AP
10:39AM  Advising Valeant's hostile bid CNBC
10:18AM  Valeant ready to raise Allergan bid to at least $200/share Reuters
10:02AM  ALLERGAN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
09:50AM  Shire (SHPG) Gains on Q3 Earnings Beat, Ups Guidance Zacks
09:47AM  Stocks to Watch: Chiquita, Allergan, Merck at The Wall Street Journal
09:40AM  Allergan Beats on Earnings, Revenues; Valeant Raises Offer Zacks
09:10AM  Allergan Comments on Valeant Letter Business Wire
09:08AM  Pharma fight: What's Allergan worth? CNBC
09:04AM  U.S. stock: Futures fall; focus on Fed at MarketWatch
09:02AM  Valeant may up bid for Allergan...again; Merck mixed results; Apple Pay mobile payment battle Hot Stock Minute
08:49AM  Valeant boosts offer for Botox maker Allergan at USA TODAY
08:09AM  Valeant Ready to Raise Offer for Botox Maker Allergan at New York Times
08:05AM  Allergan (AGN) Stock Higher Today After Possible New Valeant Pharmaceuticals (VRX) Bid at TheStreet
07:21AM  Valeant says ready to raise Allergan bid to at least $200/share Reuters
07:20AM  Wall Street struggles to keep up momentum; Merck's profit tops estimates; Apple Pay gets a setback Hot Stock Minute
07:12AM  Allergan tops Street 3Q forecasts AP
07:11AM  Valeant willing to improve Allergan offer to value of at least $200 a share at MarketWatch
07:07AM  Q3 2014 Allergan Inc Earnings Release - Before Market Open CCBN
07:00AM  Allergan Reports Third Quarter 2014 Operating Results Business Wire
06:55AM  Valeant Delivers Letter To Allergan Board PR Newswire
06:55AM  Valeant Delivers Letter To Allergan Board CNW Group
01:00AM  PRESS DIGEST- New York Times business news - Oct 27 Reuters
24-Oct-14 05:44PM  COLUMN-New details in Allergan anti-takeover campaign: Frankel Reuters
04:39PM  Botox Maker Allergan Pleaded for Goldmans Help in Valeant Fight at New York Times
01:00PM  Allergan Announces Quarterly Conference Call Business Wire
10:05AM  What Does ValueAct See in Taking an Activist Role in Fertilizers? at 24/7 Wall St.
08:55AM  Eli Lilly's Q3 Earnings In-Line but Generics Hit Revenues Zacks
08:35AM  Glaxo Gains on Q3 Earnings Beat and Restructuring Plans Zacks
23-Oct-14 05:34PM  Bill Ackman Likes 'Happy Deals' at The Wall Street Journal
08:05AM  Valeant (VRX) Beats Earnings Estimates in Q3, Shares Gain Zacks
22-Oct-14 10:15AM  Abbott Labs' (ABT) Earnings Up Y/Y in Q3, Guidance Updated Zacks
05:00AM  Learn How To Invest Defensively From This Hedge Fund Pro at Investopedia
21-Oct-14 03:09PM  Einhorn: Selloff Created Buying Opportunities, Embrace Higher Interest at TheStreet
03:04PM  Allergan keeps a few secrets, court filing shows at MarketWatch
12:42PM  Meister wants Allergan to sell for highest price CNBC
12:29PM  Valeant, Ackman: Allergan Spread 'Misleading' Info in Takeover Fight at The Wall Street Journal
10:50AM  Trade-Ideas: Allergan (AGN) Is Today's Momo Momentum Stock at TheStreet
10:45AM  Allergan says it stands by statements on Valeant Reuters
09:31AM  Deals of the Day: Reebok Reaction, Banana Development, IPO Delay at The Wall Street Journal
02:50AM  Paulson hedge fund urges Allergan bid for Shire CNBC
20-Oct-14 11:42PM  Ackman, Valeant lawyers say Allergan CEO oversaw campaign to discredit Valeant Reuters
07:39PM  Valeant hints at higher bid for Allergan at Financial Times
06:47PM  Can Valeant's Strong Q3 Entice Allergan? at Investor's Business Daily
06:20PM  Paulson Said to Urge Shire-Allergan Merger as AbbVie Talks End at Bloomberg
05:14PM  Actavis Said to Compete With Sanofi for Omega Pharma Deal at Bloomberg
03:31PM  Paulsons Hedge Fund Urges Botox-Maker Allergan to Consider Buying Shire at New York Times
03:13PM  Allergan files rebuttal to Valeant earnings at MarketWatch
01:55PM  Top Allergan holder Paulson urges deal with Shire: sources Reuters
01:53PM  Top Allergan holder Paulson urges deal with Shire -sources Reuters
01:52PM  Paulson & Co. pushes for Allergan merger with Shire: report at MarketWatch
12:51PM  Paulson Urges Allergan/Shire Tie-up at The Wall Street Journal
12:50PM  Valeant says may raise Allergan bid; beats on profit Reuters
12:15PM  [video] Report: Paulson pushing Allergan-Shire merger at CNBC
11:45AM  Jim Cramer: Valeant Pharmaceuticals and Allergan Are Winners at TheStreet
10:48AM  [$$] Valeant Pushes Business Strength at The Wall Street Journal
09:33AM  Valeant may raise Allergan bid, says it won't walk away Reuters
06:01AM  ALLERGAN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
17-Oct-14 03:29PM  The top 10 best-performing CEOs at Fortune
09:42AM  [video] Faber Report: Allergan takeover battle at CNBC
16-Oct-14 12:37PM  Ackman: Allergan tried to manipulate Valeant stock CNBC
12:37PM  [video] Ackman: Allergan tried to manipulate Valeant stock at CNBC
12:08PM  Ackman: Lawyers have documents purported to show Allergan misled on Valeant Reuters
11:10AM  Will Actavis Win Competition For Allergan's Affection? Benzinga
01:22AM  AbbVie Board To Shareholders: Vote No On Shire Buy at Investor's Business Daily
15-Oct-14 08:00AM  Harvard Business Review Ranks David Pyott One of the Top 5 CEOs in the World Business Wire
14-Oct-14 10:27AM  J&J Beats Q3 Earnings on Strong Drug Sales, Ups View Zacks
06:34AM  Time to Focus on Allergan (AGN) for Strong Earnings Growth Potential Zacks
13-Oct-14 12:22PM  Ackman, others seek what Buffett has probably in vain Yahoo Finance
09:19AM  Bill Ackman's new fund falls 6% in public debut in Amsterdam at MarketWatch
06:43AM  [video] Bill Ackman: Venezuela Could Kill Herbalife's Earnings at Bloomberg
Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and physician-dispensed skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well as tissue expanders; and facial aesthetics products. The company also holds LiRIS Program, which is in Phase II trials for the treatment of interstitial cystitis/bladder pain syndrome. It sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies, and medical practitioners. The company focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, urologists, urogynecologists, and general practitioners. It has collaboration agreements with Molecular Partners AG; Spectrum Pharmaceuticals, Inc.; and Serenity Pharmaceuticals, LLC. Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sherman Scott DExecutive Vice President, HRApr 22Option Exercise75.5810,000755,80018,223Apr 23 07:25 PM
Sherman Scott DExecutive Vice President, HRApr 22Sale163.0010,0001,630,0008,223Apr 23 07:25 PM
Sherman Scott DExecutive Vice President, HRApr 21Option Exercise73.044,500328,68012,723Apr 23 07:25 PM
Sherman Scott DExecutive Vice President, HRApr 21Sale139.854,500629,3258,223Apr 23 07:25 PM
LAVIGNE LOUIS J JRDirectorFeb 21Sale125.795,400679,2440Feb 24 07:59 PM
INGRAM DOUGLAS SPresidentFeb 21Sale125.701961,044Feb 25 05:49 PM
Diradoorian Raymond HEVPGlobal Technical OperationsFeb 19Option Exercise58.5523,0001,346,65029,401Feb 21 04:56 PM
EDWARDS JEFFREY LEVP, Fin & Bus. Dev., CFOFeb 19Option Exercise40.1638,9001,562,22455,491Feb 21 04:59 PM
Diradoorian Raymond HEVPGlobal Technical OperationsFeb 19Sale126.6623,0002,913,1116,401Feb 21 04:56 PM
HUDSON DAWN EDirectorFeb 19Sale126.354,200530,68311,600Feb 21 05:14 PM
EDWARDS JEFFREY LEVP, Fin & Bus. Dev., CFOFeb 19Sale126.3938,9004,916,49316,591Feb 21 04:59 PM
Sherman Scott DExecutive Vice President, HRFeb 18Option Exercise75.585,000377,90013,220Feb 19 02:44 PM
Sherman Scott DExecutive Vice President, HRFeb 18Sale125.745,000628,7008,220Feb 19 02:44 PM
INGRAM DOUGLAS SPresidentFeb 14Option Exercise55.9884,0004,701,90085,058Feb 19 02:41 PM
Sherman Scott DExecutive Vice President, HRFeb 14Sale124.761708,220Feb 19 02:44 PM
INGRAM DOUGLAS SPresidentFeb 14Sale124.4084,00010,449,4321,058Feb 19 02:41 PM
PYOTT DAVID E IChairman of the Board and CEOFeb 12Option Exercise36.15252,0009,109,800417,000Feb 13 05:49 PM
BARLOW JAMES FSR. VP, Corp. Controller (PAO)Feb 12Option Exercise65.9223,8751,573,76930,754Feb 13 05:54 PM
PYOTT DAVID E IChairman of the Board and CEOFeb 12Sale123.12252,00031,025,560165,000Feb 13 05:49 PM
BARLOW JAMES FSR. VP, Corp. Controller (PAO)Feb 12Sale123.5223,8752,949,0416,879Feb 13 05:54 PM
Diradoorian Raymond HEVPGlobal Technical OperationsFeb 11Option Exercise55.9817,000951,57523,401Feb 13 05:56 PM
LAVIGNE LOUIS J JRDirectorFeb 11Option Exercise55.2054,6003,014,01924,123Feb 13 05:59 PM
Diradoorian Raymond HEVPGlobal Technical OperationsFeb 11Sale121.8217,0002,070,9576,401Feb 13 05:56 PM
LAVIGNE LOUIS J JRDirectorFeb 11Sale122.3954,6006,682,69612,723Feb 13 05:59 PM
Sherman Scott DExecutive Vice President, HRFeb 10Option Exercise75.585,000377,90013,325Feb 11 08:41 PM
Sherman Scott DExecutive Vice President, HRFeb 10Sale120.005,000600,0008,325Feb 11 08:41 PM
EDWARDS JEFFREY LEVP, Fin & Bus. Dev., CFOFeb 07Option Exercise64.47105,5006,801,585122,371Feb 11 08:37 PM
Sherman Scott DExecutive Vice President, HRFeb 07Option Exercise73.044,500328,68012,825Feb 11 08:41 PM
EDWARDS JEFFREY LEVP, Fin & Bus. Dev., CFOFeb 07Sale117.74105,50012,421,04316,871Feb 11 08:37 PM
Sherman Scott DExecutive Vice President, HRFeb 07Sale118.554,500533,4848,325Feb 11 08:41 PM
Whitcup Scott MExecutive VP, R&D, CSOJan 14Option Exercise55.9842,0002,350,95059,327Jan 15 06:24 PM
Whitcup Scott MExecutive VP, R&D, CSOJan 14Sale117.8042,0004,947,60017,327Jan 15 06:24 PM
Whitcup Scott MExecutive VP, R&D, CSOJan 08Option Exercise55.9842,0002,350,95059,327Jan 10 06:37 PM
Whitcup Scott MExecutive VP, R&D, CSOJan 08Sale113.8042,0004,779,60017,327Jan 10 06:37 PM
Gangolli Julian SCVP & Pres, North AmericaDec 27Option Exercise53.7152,5002,819,77545,547Dec 30 05:18 PM
Gangolli Julian SCVP & Pres, North AmericaDec 27Sale110.0552,5005,777,5508,047Dec 30 05:18 PM
Whitcup Scott MExecutive VP, R&D, CSODec 20Option Exercise36.1533,0001,192,95033,827Dec 20 07:41 PM
Whitcup Scott MExecutive VP, R&D, CSODec 20Option Exercise0.0033,000033,827Jan 06 06:27 PM
Whitcup Scott MExecutive VP, R&D, CSODec 20Sale108.8033,0003,590,40017,327Jan 06 06:27 PM
Whitcup Scott MExecutive VP, R&D, CSODec 20Sale108.8033,0003,590,40017,327Dec 20 07:41 PM
HUDSON DAWN EDirectorNov 27Sale97.463,000292,38215,800Dec 02 04:52 PM